Notably, about one in four of these patients did not carry a type 2 diabetes diagnosis , suggesting that a substantial portion of GLP-1 use is being driven by weight loss and other emerging indications outside of diabetes care (Figure 2)
however, it has associated side effects of weight gain and adverse metabolic effects (increasing the potential risk of high cholesterol or diabetes)
Back Braun, K, von Voss, P, Gotfredsen, CF, et al (1 Jan 2007) 'Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-iv inhibitor, vildagliptin, does not', Diabetes , 56/1, 815
doi: 10.1016/j.cmet.2021.11.010 193
Who is NAC for
Retatrutide vs Tirzepatide One of the most common comparisons in peptide research is Retatrutide vs Tirzepatide